Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Деносумаб (AMG-162) в профилактике остеопороза, вызванного приемом ингибиторов ароматазы у больных раком молочной железы в адъювантной терапии и у больных раком предстательной железы при полной андрогенной блокаде
Деносумаб (AMG-162) в профилактике остеопороза, вызванного приемом ингибиторов ароматазы у больных раком молочной железы в адъювантной терапии и у больных раком предстательной железы при полной андрогенной блокаде
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamo-xifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
2. Thurlimann B, Keshaviah A, Coates A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1–98 Collaborative Group. N Engl J Med 2005; 353: 2747–57.
3. Coombes RC, Hall E, Snowdon C et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen--updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1): S7.
4. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
5. Perez E et al. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA-17. J Clin Oncol 2006; 24(22): 3629–35.
6. Gnant M et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. N Engl J Med 2009; 360: 7.
7. Brufsky A et al. Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 2008; 13 (5): 503–14.
8. Lester J et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin Cancer Res 2008; 14, 6336.
9. Lester J et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26(suppl 15): 554.
10. Anderson D et al. Nature 1997; 390: 175–9.
11. Lacey D, Timms E, Tan H et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76.
12. Ellis G, Bone H, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
13. Smith M et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361: 745–55.
14. Cummings S et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 2009; 8: 361.
15. Powles T et al. Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer. Breast Cancer Res. 2006; 8: R13.
2. Thurlimann B, Keshaviah A, Coates A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1–98 Collaborative Group. N Engl J Med 2005; 353: 2747–57.
3. Coombes RC, Hall E, Snowdon C et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen--updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1): S7.
4. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
5. Perez E et al. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA-17. J Clin Oncol 2006; 24(22): 3629–35.
6. Gnant M et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. N Engl J Med 2009; 360: 7.
7. Brufsky A et al. Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 2008; 13 (5): 503–14.
8. Lester J et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin Cancer Res 2008; 14, 6336.
9. Lester J et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26(suppl 15): 554.
10. Anderson D et al. Nature 1997; 390: 175–9.
11. Lacey D, Timms E, Tan H et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76.
12. Ellis G, Bone H, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
13. Smith M et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361: 745–55.
14. Cummings S et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 2009; 8: 361.
15. Powles T et al. Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer. Breast Cancer Res. 2006; 8: R13.
Авторы
М.Р.Личиницер, Н.Н.Семенов
Отделение химиотерапии и комбинированного лечения злокачественных опухолей РОНЦ им. Н.Н.Блохина РАМН, Москва
Отделение химиотерапии и комбинированного лечения злокачественных опухолей РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.